Bobby V. Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bobby V. Khan has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Srikanth Sola
Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia
6 shared publications Anbu Pandian
Department of Cardiology, Emory University, Atlanta, GA
3 shared publicationsFaiz A. Cheema
From the Division of Cardiology, Emory University School of Medicine and the Vascular Research Laboratory, Grady Memorial Hospital, Atlanta, GA
3 shared publicationsNadya Merchant
Department of Cardiology, Emory University, 69 Jesse Hill Drive SE, Atlanta, GA30303, USA
3 shared publicationsSampath Parthasarathy
From the Division of Cardiology, Emory University School of Medicine, Atlanta, GA
3 shared publicationsAmar D. Patel
From Emory University School of Medicine, Division of Cardiology, Atlanta, GA;1 and Beckman Research Institute of City of Hope Medical Center, Duarte, CA2
2 shared publications
Latest Publications
- 1 April 2011
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 104 (4) , 257-263
Protected Carotid Artery Stenting in Patients at High Risk for Carotid Endarterectomy
Objectives: To compare the 30-day, six-month, and one-year outcomes of carotid artery stenting (CAS) and carotid endarterectomy (CEA) in male veterans, and to identify any predictors of adverse outcomes. CAS has been shown to be non-inferior to CEA in patients at high-risk for CEA. The outcome of CAS compared to low-risk CEA is less clear. Methods: Retrospective analysis of 96 consecutive...
- 1 April 2011
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 104 (4) , 257-263
Protected Carotid Artery Stenting in Patients at High Risk for Carotid Endarterectomy
Objectives: To compare the 30-day, six-month, and one-year outcomes of carotid artery stenting (CAS) and carotid endarterectomy (CEA) in male veterans, and to identify any predictors of adverse outcomes. CAS has been shown to be non-inferior to CEA in patients at high-risk for CEA. The outcome of CAS compared to low-risk CEA is less clear. Methods: Retrospective analysis of 96 consecutive...
- 1 November 2010
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 5 (6) , 835-837
Is there a role for pleiotropic effects of atorvastatin and fenofibrate in the metabolic syndrome and prediabetes?
The beneficial use of fibrates and statins has been observed in previous studies among patients with dyslipidemia, including those with glucose metabolism abnormalities. The paper under evaluation highlights these benefits and provides insight. Specifically, these findings are observed in patients who have prediabetes and metabolic syndrome (MS), and are taking atorvastatin or fenofibrate. The paper documents that both drugs have multiple pleiotropic effects on MS patients. Furthermore, these effects may be determined by prediabetes type. The results strengthen previous knowledge and offer new understanding, as no previous study has investigated whether the type of prediabetes can determine extra- lipid effects and cardiovascular risk factors in MS patients.
- 1 November 2010
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 5 (6) , 835-837
Is there a role for pleiotropic effects of atorvastatin and fenofibrate in the metabolic syndrome and prediabetes?
The beneficial use of fibrates and statins has been observed in previous studies among patients with dyslipidemia, including those with glucose metabolism abnormalities. The paper under evaluation highlights these benefits and provides insight. Specifically, these findings are observed in patients who have prediabetes and metabolic syndrome (MS), and are taking atorvastatin or fenofibrate. The paper documents that both drugs have multiple pleiotropic effects on MS patients. Furthermore, these effects may be determined by prediabetes type. The results strengthen previous knowledge and offer new understanding, as no previous study has investigated whether the type of prediabetes can determine extra- lipid effects and cardiovascular risk factors in MS patients.
- 8 April 2010
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 25 (3) , 196-202
Effects of nebivolol in obese African Americans with hypertension (NOAAH): markers of inflammation and obesity in response to exercise-induced stress
We sought to determine whether the antihypertensive drug nebivolol has beneficial effects on vascular markers of inflammation and oxidation in obese African-American patients with hypertension when exposed to exercise-induced stress. Forty-three obese, African-American subjects with hypertension were treated with nebivolol (5–10 mg/day) for 8 weeks. Before treatment the subjects underwent an exercise treadmill study to a level of eight metabolic equivalents. Circulating levels of soluble interleukin-6 (sIL-6), vascular cell adhesion molecule (VCAM-1), adiponectin and leptin were measured at pre-treadmill, and 1 min, 30 min, 60 min and 24 h after treadmill. After the 8-week treatment period, exercise treadmill study and the measurement of markers were repeated. Treatment with nebivolol reduced levels of sVCAM-1 at pre-exercise by 21% and at 1 and 30 min by 12.5 and 20%, respectively (PPP=0.012) and decreased levels of leptin by 32% (P<0.005 from pre-treatment). Treatment with nebivolol improves markers of inflammation and obesity in a high-risk African-American population. Moreover, this effect is potentiated in response to exercise-induced stress. These results suggest that nebivolol differentially regulates markers of inflammation and obesity, thereby providing vascular protection.
- 8 April 2010
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 25 (3) , 196-202
Effects of nebivolol in obese African Americans with hypertension (NOAAH): markers of inflammation and obesity in response to exercise-induced stress
We sought to determine whether the antihypertensive drug nebivolol has beneficial effects on vascular markers of inflammation and oxidation in obese African-American patients with hypertension when exposed to exercise-induced stress. Forty-three obese, African-American subjects with hypertension were treated with nebivolol (5–10 mg/day) for 8 weeks. Before treatment the subjects underwent an exercise treadmill study to a level of eight metabolic equivalents. Circulating levels of soluble interleukin-6 (sIL-6), vascular cell adhesion molecule (VCAM-1), adiponectin and leptin were measured at pre-treadmill, and 1 min, 30 min, 60 min and 24 h after treadmill. After the 8-week treatment period, exercise treadmill study and the measurement of markers were repeated. Treatment with nebivolol reduced levels of sVCAM-1 at pre-exercise by 21% and at 1 and 30 min by 12.5 and 20%, respectively (PPP=0.012) and decreased levels of leptin by 32% (P<0.005 from pre-treatment). Treatment with nebivolol improves markers of inflammation and obesity in a high-risk African-American population. Moreover, this effect is potentiated in response to exercise-induced stress. These results suggest that nebivolol differentially regulates markers of inflammation and obesity, thereby providing vascular protection.
- 4 February 2010
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 15 (1) , 47-52
Effects of Labetalol on Hemodynamic Parameters and Soluble Biomarkers of Inflammation in Acute Coronary Syndrome in Patients With Active Cocaine Use
Cocaine use is associated with increased cardiovascular mortality and can promote acute coronary syndrome (ACS). Use of β-blockers is controversial in patients who use cocaine, and the safety and efficacy of these medications in ACS in patients actively using cocaine is unknown. We enrolled 90 patients with ACS and positive urine drug screen for cocaine. Patients received standard ACS therapy plus either labetalol (n = 60) or diltiazem (n = 30). Blood pressure and heart rate were measured at baseline and 48 hours. Levels of serum CD40 ligand, interleukin (IL)-6, and choline at baseline and 48 hours were determined. There were no baseline differences in hemodynamics or serum levels of inflammatory markers between the labetalol and diltiazem groups. Both groups experienced a significant and equivalent decrease in BP and HR at 48 hours compared with baseline. At 48 hours of treatment, there were significant decreases of 17% in CD40 ligand (P < .005) and 16% in IL-6 (P < .005) but no change in choline in the diltiazem group. Furthermore, in the labetalol group, there were significant differences of 30% in CD40 ligand (P < .005 time and group comparison), 22% in IL-6 (P < .005 time and group comparison), and 18% in choline (P < .005 time and group comparison). There were no adverse events during hospitalization in any patients who received labetalol. In conclusion, labetalol appears to be safe in cocaine-associated ACS. Furthermore, labetalol provides a beneficial hemodynamic response and, in comparison to diltiazem, potentiates an anti-inflammatory vascular response in this setting.
- 4 February 2010
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 15 (1) , 47-52
Effects of Labetalol on Hemodynamic Parameters and Soluble Biomarkers of Inflammation in Acute Coronary Syndrome in Patients With Active Cocaine Use
Cocaine use is associated with increased cardiovascular mortality and can promote acute coronary syndrome (ACS). Use of β-blockers is controversial in patients who use cocaine, and the safety and efficacy of these medications in ACS in patients actively using cocaine is unknown. We enrolled 90 patients with ACS and positive urine drug screen for cocaine. Patients received standard ACS therapy plus either labetalol (n = 60) or diltiazem (n = 30). Blood pressure and heart rate were measured at baseline and 48 hours. Levels of serum CD40 ligand, interleukin (IL)-6, and choline at baseline and 48 hours were determined. There were no baseline differences in hemodynamics or serum levels of inflammatory markers between the labetalol and diltiazem groups. Both groups experienced a significant and equivalent decrease in BP and HR at 48 hours compared with baseline. At 48 hours of treatment, there were significant decreases of 17% in CD40 ligand (P < .005) and 16% in IL-6 (P < .005) but no change in choline in the diltiazem group. Furthermore, in the labetalol group, there were significant differences of 30% in CD40 ligand (P < .005 time and group comparison), 22% in IL-6 (P < .005 time and group comparison), and 18% in choline (P < .005 time and group comparison). There were no adverse events during hospitalization in any patients who received labetalol. In conclusion, labetalol appears to be safe in cocaine-associated ACS. Furthermore, labetalol provides a beneficial hemodynamic response and, in comparison to diltiazem, potentiates an anti-inflammatory vascular response in this setting.
- Open Access
- 3 December 2009
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 11 (12) , 720-725
Nebivolol in High‐Risk, Obese African Americans With Stage 1 Hypertension: Effects on Blood Pressure, Vascular Compliance, and Endothelial Function
The authors sought to determine whether nebivolol treatment results in changes in blood pressure (BP), nitric oxide bioavailability, and vascular function in obese African Americans with recently diagnosed stage 1 hypertension. Forty‐three obese, hypertensive African Americans (mean BP: systolic, 148.8±14.3 mm Hg; diastolic, 90.4±8.2 mm Hg) were treated with nebivolol (5–10 mg/d) for 8 weeks. Primary outcomes were change in systolic and diastolic BP and efficacy in reaching normotensive BP. Mean systolic BP decreased by 9.2±14 mm Hg (P<.005) and diastolic BP decreased 6.8±9 mm Hg (P<.005) with 8 weeks of therapy. Significant improvements were seen in arterial compliance with nebivolol treatment as measured by aortic augmentation index (P<.005) and time to wave reflection (P=.013). Nebivolol treatment improved endothelial function as measured by flow‐mediated dilation (P<.005). Levels of erythrocyte cellular superoxide dismutase increased with nebivolol, indirectly suggesting increased bioavailability of nitric oxide (P<.005). Monotherapy with nebivolol in obese, hypertensive African Americans results in significant systolic and diastolic BP reduction by mechanisms that include improved vascular function and compliance.
- 3 December 2009
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 11 (12) , 720-725
Open AccessNebivolol in High‐Risk, Obese African Americans With Stage 1 Hypertension: Effects on Blood Pressure, Vascular Compliance, and Endothelial Function
The authors sought to determine whether nebivolol treatment results in changes in blood pressure (BP), nitric oxide bioavailability, and vascular function in obese African Americans with recently diagnosed stage 1 hypertension. Forty‐three obese, hypertensive African Americans (mean BP: systolic, 148.8±14.3 mm Hg; diastolic, 90.4±8.2 mm Hg) were treated with nebivolol (5–10 mg/d) for 8 weeks. Primary outcomes were change in systolic and diastolic BP and efficacy in reaching normotensive BP. Mean systolic BP decreased by 9.2±14 mm Hg (P<.005) and diastolic BP decreased 6.8±9 mm Hg (P<.005) with 8 weeks of therapy. Significant improvements were seen in arterial compliance with nebivolol treatment as measured by aortic augmentation index (P<.005) and time to wave reflection (P=.013). Nebivolol treatment improved endothelial function as measured by flow‐mediated dilation (P<.005). Levels of erythrocyte cellular superoxide dismutase increased with nebivolol, indirectly suggesting increased bioavailability of nitric oxide (P<.005). Monotherapy with nebivolol in obese, hypertensive African Americans results in significant systolic and diastolic BP reduction by mechanisms that include improved vascular function and compliance.
- 3 December 2009
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 11 (12) , 775-776
Do the Current Medical and Economic Times Dictate the Need for the “Polypill”?
- 3 December 2009
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 11 (12) , 775-776
Do the Current Medical and Economic Times Dictate the Need for the “Polypill”?
- Open Access
- 1 November 2009
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. 1, 181-191
Raising HDL cholesterol in women
Raising HDL cholesterol in women Danny J Eapen1, Girish L Kalra1, Luay Rifai1, Christina A Eapen2, Nadya Merchant1, Bobby V Khan11Emory University School of Medicine, Atlanta, GA, USA; 2University of South Florida School of Medicine, Tampa, FL, USA High-density lipoprotein cholesterol (HDL-C) concentration is essential in the determination of coronary heart disease (CHD) risk in women. This is especially true in the postmenopausal state, where lipid profiles and CHD risk mimic that of age-matched men. Thus, interventions designed to reduce CHD risk by raising HDL-C levels may have particular significance during the transition to menopause. This review discusses HDL-C-raising therapies and the role of HDL in the primary prevention of CHD in women. Lifestyle-based interventions such as dietary change, aerobic exercise regimens, and smoking cessation are initial steps that are effective in raising HDL-C, and available data suggest women respond similarly to men with these interventions. When combined with pharmacotherapy, the effects of these lifestyle alterations are further amplified. Though studies demonstrating gender-specific differences in therapy are limited, niacin continues to be the most effective agent in raising HDL-C levels, especially when used in combination with fibrate or statin therapy. Emerging treatments such as HDL mimetic therapy show much promise in further raising HDL-C levels and improving cardiovascular outcomes.Keywords: high-density lipoprotein, HDL, women, cholesterol, heart disease
- 1 November 2009
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. 1, 181-191
Open AccessRaising HDL cholesterol in women
Raising HDL cholesterol in women Danny J Eapen1, Girish L Kalra1, Luay Rifai1, Christina A Eapen2, Nadya Merchant1, Bobby V Khan11Emory University School of Medicine, Atlanta, GA, USA; 2University of South Florida School of Medicine, Tampa, FL, USA High-density lipoprotein cholesterol (HDL-C) concentration is essential in the determination of coronary heart disease (CHD) risk in women. This is especially true in the postmenopausal state, where lipid profiles and CHD risk mimic that of age-matched men. Thus, interventions designed to reduce CHD risk by raising HDL-C levels may have particular significance during the transition to menopause. This review discusses HDL-C-raising therapies and the role of HDL in the primary prevention of CHD in women. Lifestyle-based interventions such as dietary change, aerobic exercise regimens, and smoking cessation are initial steps that are effective in raising HDL-C, and available data suggest women respond similarly to men with these interventions. When combined with pharmacotherapy, the effects of these lifestyle alterations are further amplified. Though studies demonstrating gender-specific differences in therapy are limited, niacin continues to be the most effective agent in raising HDL-C levels, especially when used in combination with fibrate or statin therapy. Emerging treatments such as HDL mimetic therapy show much promise in further raising HDL-C levels and improving cardiovascular outcomes.Keywords: high-density lipoprotein, HDL, women, cholesterol, heart disease
- Open Access
- 1 October 2008
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 4 (5) , 1001-1009
Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin Anbu Pandian1, Anjali Arora2, Laurence S Sperling1, Bobby V Khan11Emory University School of Medicine and Grady Memorial Hospital Vascular Research Atlanta, Georgia USA; 2Sir Ganga Ram Hospital, New Delhi, India Dyslipidemia is a major risk factor in the initiation and progression of cardiovascular diseases such as atherosclerosis. Several pharmacological agents have been developed over the past 50 years which target various lipid components such as low density lipoprotein (LDL) cholesterol, triglyceride, and high density lipoprotein (HDL) cholesterol. Similar to other risk factors such as hypertension and diabetes mellitus, the management of dyslipidemia can be complicated and may require combination therapy for effective treatment. This review discusses the biochemical mechanisms of action and clinical uses for simvastatin (the most widely available and commercially prescribed statin) and niacin, and the combination of these agents in the management and treatment of dyslipidemia.Keywords: dyslipidemia, HDL cholesterol, triglyceride, statin, niacin
- 1 October 2008
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 4 (5) , 1001-1009
Open AccessTargeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin Anbu Pandian1, Anjali Arora2, Laurence S Sperling1, Bobby V Khan11Emory University School of Medicine and Grady Memorial Hospital Vascular Research Atlanta, Georgia USA; 2Sir Ganga Ram Hospital, New Delhi, India Dyslipidemia is a major risk factor in the initiation and progression of cardiovascular diseases such as atherosclerosis. Several pharmacological agents have been developed over the past 50 years which target various lipid components such as low density lipoprotein (LDL) cholesterol, triglyceride, and high density lipoprotein (HDL) cholesterol. Similar to other risk factors such as hypertension and diabetes mellitus, the management of dyslipidemia can be complicated and may require combination therapy for effective treatment. This review discusses the biochemical mechanisms of action and clinical uses for simvastatin (the most widely available and commercially prescribed statin) and niacin, and the combination of these agents in the management and treatment of dyslipidemia.Keywords: dyslipidemia, HDL cholesterol, triglyceride, statin, niacin
- 30 April 2008
- Published by Elsevier in Heart Failure Clinics
- Vol. 4 (2) , 171-176
Investigations of Statins in Heart Failure: Inflammatory Biomarkers and Hormones
- 30 April 2008
- Published by Elsevier in Heart Failure Clinics
- Vol. 4 (2) , 171-176
Investigations of Statins in Heart Failure: Inflammatory Biomarkers and Hormones
- 20 March 2008
- Published by Wiley in Journal of the CardioMetabolic Syndrome
- Vol. 3 (1) , 12-17
Effects of Angiotensin‐Converting Enzyme Inhibitor Therapy on Levels of Inflammatory Markers in Response to Exercise‐Induced Stress: Studies in the Metabolic Syndrome
The authors sought to determine whether the angiotensin‐converting enzyme (ACE) inhibitor perindopril has beneficial effects on vascular markers of inflammation in patients with the metabolic syndrome when exposed to exercise‐induced stress. Thirty patients with the metabolic syndrome were randomized to perindopril (4 mg/d) or placebo in a double‐blind fashion for 4 weeks. Prior to treatment, the patients underwent an exercise treadmill study to a level of 8 metabolic equivalents. Circulating monocyte CD11b expression, levels of soluble interleukin 6 (sIL‐6), and levels of vascular cell adhesion molecule‐1 (VCAM‐1) were measured. After the treatment period, exercise treadmill study and measurement of markers were repeated. Treatment with perindopril reduced sIL‐6 levels at pre‐exercise by 22% and at 1 and 30 minutes by 30% and 33%, respectively (P<.005). Levels of soluble VCAM‐1 in perindopril‐treated patients were reduced at pre‐exercise by 25% and at 1 and 30 minutes by 31% and 37%, respectively. Treatment with perindopril reduced monocyte CD11b expression by 25%. In response to exercise‐induced physical stress, the addition of an ACE inhibitor differentially regulates markers of inflammation, thereby providing potential vascular protection in the metabolic syndrome.
- 20 March 2008
- Published by Wiley in Journal of the CardioMetabolic Syndrome
- Vol. 3 (1) , 12-17
Effects of Angiotensin‐Converting Enzyme Inhibitor Therapy on Levels of Inflammatory Markers in Response to Exercise‐Induced Stress: Studies in the Metabolic Syndrome
The authors sought to determine whether the angiotensin‐converting enzyme (ACE) inhibitor perindopril has beneficial effects on vascular markers of inflammation in patients with the metabolic syndrome when exposed to exercise‐induced stress. Thirty patients with the metabolic syndrome were randomized to perindopril (4 mg/d) or placebo in a double‐blind fashion for 4 weeks. Prior to treatment, the patients underwent an exercise treadmill study to a level of 8 metabolic equivalents. Circulating monocyte CD11b expression, levels of soluble interleukin 6 (sIL‐6), and levels of vascular cell adhesion molecule‐1 (VCAM‐1) were measured. After the treatment period, exercise treadmill study and measurement of markers were repeated. Treatment with perindopril reduced sIL‐6 levels at pre‐exercise by 22% and at 1 and 30 minutes by 30% and 33%, respectively (P<.005). Levels of soluble VCAM‐1 in perindopril‐treated patients were reduced at pre‐exercise by 25% and at 1 and 30 minutes by 31% and 37%, respectively. Treatment with perindopril reduced monocyte CD11b expression by 25%. In response to exercise‐induced physical stress, the addition of an ACE inhibitor differentially regulates markers of inflammation, thereby providing potential vascular protection in the metabolic syndrome.